Posts

4Moving Biotech website is online!

It is our great pleasure to announce that 4Moving Biotech website is online! ​

4Moving Biotech is a French biotech start-up company, subsidiary of 4P-Pharma, dedicated to the clinical development of 4P004, a first-in-class disease-modifying drug for osteoarthritis.​

Click on the link and take a look! Exciting news will be announced!

4Moving Biotech announces a closing of €2M investment to implement 4P004 phase 1 clinical trial on Osteoarthritis patients

4Moving Biotech, announces that it has closed a €2M investment agreement with 4P- Pharma, SATT Lutech, French Tech Seed and business angels. 4Moving Biotech is the spin-off of 4P-Pharma focusing on the development of 4P004, a first-in-class Disease Modifying OsteoArthritis Drug (DMOAD). 4Moving Biotech intends to use the proceeds to initiate a phase I clinical trial on people suffering from osteoarthritis.

“The incorporation and development of 4Moving Biotech is the proof of the relevancy of 4P-Pharma business model: bringing to patient the best innovations from academic scientists, in a relatively short time and with limited risks. […]”, says Revital Rattenbach, Chairwoman of 4Moving Biotech and 4P-Pharma.

 

“This fundraising gives us an extraordinary opportunity to conduct our first clinical trial in women and men suffering from OA with 4P004. […]”, adds Francis Berenbaum, CEO/CMO of 4Moving Biotech, Head of rheumatology department at Saint-Antoine Hospital (AP-HP), and Professor at Sorbonne University (Paris, France).

Read the full press release:
EN: 20210429_PR_4Mov_Closing_vEN
FR: 20210429_PR_4Mov_Financement_FR

Press contact 4Moving Biotech
Roselina Lam, Business Development and Licensing Manager
E-mail: contact@4moving-biotech.com

4Moving Biotech received the Seal of Excellence from the European Commission

4Moving Biotech, our spin-off company centered on 4P004, received the Seal of Excellence from the European Commission, for its application submitted to the Horizon 2020 Accelerator (SME instrument). This award is related to the development of 4P004, our disease modifier treatment for osteoarthritis.

The Seal of Excellence is a high-quality label awarded by a panel of international independent experts. 4Moving Biotech project was scored as a high-quality proposal in a highly competitive evaluation process, it recognizes the high value of our breakthrough treatment at EU level.

4Moving Biotech au congrès de la SFR

Le Pr. Francis Berenbaum (chef du service de Rhumatologie de l’Hôpital Saint-Antoine et professeur de rhumatologie à Sorbonne Université, Paris) présentera nos résultats sur le projet 4P004 au 33ème congrès de la Société Française de Rhumatologie (SFR), du 13 au 16 décembre 2020, édition digitale.

Sa présentation, intitulée « Le liraglutide comme traitement intra-articulaire potentiel pour la régénération du cartilage dans l’arthrose : études in vitro et in vivo supportant un effet pro-chondrogénique » (#O.068) sera visible le dimanche 13 décembre en vidéo à la demande dans la session scientifique arthrose.

Pour plus d’informations : https://sfr2020.process.y-congress.com/ScientificProcess/schedule/index.html